Skip to main content

Table 1 Summary of studies investigating the relationship between apoCIII and cardiovascular risk

From: The emerging role of apolipoprotein C-III: beyond effects on triglyceride metabolism

Study Study design Study population (n) Mean age (y) Male (%) apoCIII levels (mg/dl) Lipid levels (mg/dl) Key study findings
In plasma In HDL TG TC HDL-C LDL-C
Olivieri et al. [19] prospective study CVD patients (n = 633) 60.2 81.5 % 11.3a NR 154.9 220.8 46.3 147.9 Serum apoCIII ≥ 10.5 mg/dl represents an independent risk factor of overall (HR, 2.22; 95 % CI, 1.16–4.24; P = 0.016) and cardiovascular mortality (HR, 2.35; 95 % CI, 1.19–4.62; P = 0.014).
Olivieri et al. [20] retrospective study CVD patients (n = 687) vs CVD-free patients (n = 246) 60.6 vs 57.5 81.0 % vs 71.0 % 11.4 vs 10.2 NR 152.2 vs 117.7 221.2 vs 212.7 46.7 vs 55.6 147.9 vs 137.1 Increased concentration of apoCIII is associated with elevated risk of venous thrombosis (β, 0.192; 95 % CI, 0.109–0.274; P < 0.001).
Jensen et al. [22] case-control study CVD patients (NHS-women: n = 286; HPFS-men: n = 348) vs controls (NHS-women: n = 286; HPFS-men: n = 351) NHS-women: 60.2 vs 60.1; HPFS-men: 64.3 vs 64.2 54.9 % vs 55.1 % NR NHS-women: 12 vs 12; HPFS-men: 12 vs 11 NHS-women: 106.2 vs 88.5; HPFS-men: 115.0 vs 97.3 NHS-women: 234.4 vs 230.5; HPFS-men: 218.1 vs 209.3 NHS-women: 68.0 vs 72.6; HPFS-men: 46.7 vs 48.6 NHS-women: 148.3 vs 142.5; HPFS-men: 135.1 vs 125.9 HDL with apoCIII (OR, 1.18; 95 % CI, 1.03–1.34; P = 0.01) and HDL without apoCIII (OR, 0.66; 95 % CI, 0.53–0.83; P = 0.0001) are oppositely related to CVD risk.
Talayero et al. [23] case-control study Obese subjects (n = 20) vs normal weight subjects (n = 20) 51 vs 51 35 % vs 35 % 13.2 vs 7.5 11.9 vs 6.7 153 vs 83 210 vs 187 50 vs 65 130 vs 105 ApoCIII containing HDL particles (11.4 vs 5.2) and apoCIII concentration in HDL particles (11.9 vs 6.7) are significantly higher in obese subjects.
Chang et al. [24] case-control study CVD patients (n = 90) vs non-CVD patients (n = 200) 57.4 vs 53.4 80 % vs 48 % 17.4 vs 18.9 12.3 vs 9.4 261.9 vs 223.2 244.8 vs 224.3 37.0 vs 42.5 174.6 vs 165.5 HDL apoCIII to VLDL apoCIII ratio is considered as a more reliable marker to predict CVD (OR, 2.04; 95 % CI, 1.46–2.84; P < 0.0001).
Xiong et al. [25] case-control study CVD patients (n = 120) vs Non-CVD patients (n = 80) 55.5 vs 51.3 76.7 % vs 55.0 % 12.0 vs 12.7 25.1vs 21.0b 155.8 vs 143.4 173.4 vs 181.9 39.4 vs 47.9 111.2 vs 117.0 HDL apoCIII is an independent predictor of CVD (OR, 1.04; 95 % CI, 1.00–1.08; P = 0.039).
  1. ApoCIII indicates apolipoprotein CIII, HDL high density lipoprotein, TG triglyceride, TC total cholesterol, LDL-C low density lipoprotein-cholesterol, CVD cardiovascular disease, NHS Nurses’ Health Study, HPFS Health Professional Follow-up Study, NR not reported
  2. ain serum
  3. bug/mg HDL